Topas Therapeutics raises EUR22m in Series B financing
Topas Therapeutics (Topas), a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, has closed a EUR22 million (~USD26 million) Series B financing round. New investors Vesalius BioCapital III and BioMedPartners co-led this transaction, which included participation from all of Topas’ existing investors. The funding